Business & Finance
CureVac in discussions with EU about where to deploy its COVID-19 vaccine
1 July 2021 -

German biopharmaceutical company CureVac N.V. (Nasdaq:CVAC) has said it is discussions with the European Union about where in the world to best deploy its experimental COVID-19 vaccine if it wins approval, Reuters news agency reported on Thursday.

CureVac had said late on Wednesday that its COVID-19 vaccine was only 48% effective in the final analysis of a mass trial but efficacy was 77% in the age group younger than 60 years when considering only moderate to severe symptoms and excluding cases of mild disease.

Many low and middle-income countries, which have fallen far behind developed nations in the global vaccination campaign, have a younger overall population than Europe.

"This is about a broad approach to vaccinate the world population," CureVac's CEO Franz-Werner Haas stated.

The company's only major supply deal is with the European Union, which last year secured up to 405 million doses of the vaccine, of which 180 million doses were optional.